Skip to content

San Bernardino Sun

45°F
Wednesday, January 21st 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

4.490 +0.170 (+3.94%)
Streaming Delayed Price Updated: 10:29 AM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs ↗
FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre upon EBVALLO approval. 
Via Benzinga
News headline image
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Insights into Atara Biotherapeutics's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip ↗
CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns. 
Via Stocktwits
News headline image
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
US Stocks Edge Lower; Retail Sales Increase Less Than Expected ↗
 
Via Benzinga
News headline image
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Sidoti Events, LLC's Virtual November Micro-Cap Conference
Via ACCESSWIRE
News headline image
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings ↗
 
Via Benzinga
News headline image
Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On? ↗
Atara Biotherapeutics shares are trading higher by 20% Wednesday morning. The company announced a $36 million registered direct offering. 
Via Benzinga
News headline image
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q2 2024 ↗
ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.